Get the Stockscreener App
24.41
2.63%
0.6328
Apellis Pharmaceuticals Inc stock is traded at $24.41, with a volume of 720.62K.
It is up +2.63% in the last 24 hours and up +28.45% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$23.78
Open:
$23.85
24h Volume:
720.62K
Relative Volume:
0.28
Market Cap:
$3.09B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-12.03
EPS:
-2.03
Net Cash Flow:
$-205.58M
1W Performance:
+14.85%
1M Performance:
+28.45%
6M Performance:
+24.65%
1Y Performance:
-29.54%
1-Day Range:
$23.69
$24.45
1-Week Range:
$21.16
$24.45
52-Week Range:
$16.10
$35.70
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
24.42 | 3.01B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.81 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
720.34 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
893.14 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.61 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
192.17 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-15-25 | Initiated | Wells Fargo | Overweight |
| Sep-26-25 | Downgrade | Goldman | Neutral → Sell |
| May-09-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-21-24 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-25-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-16-24 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Neutral |
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
Mizuho Lowers Price Target on Apellis Pharmaceuticals (APLS) Amid Ongoing Eye Disease Therapy Challenges - MSN
Jump Financial LLC Buys 293,075 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Technical Reactions to APLS Trends in Macro Strategies - news.stocktradersdaily.com
Marshall Wace LLP Buys 2,681,263 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Norges Bank Takes Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 6.2%Still a Buy? - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Average Rating of "Hold" by Analysts - MarketBeat
Apellis Pharmaceuticals (APLS): Valuation Check After Positive EMPAVELI Kidney Data and New FDA Approval - Yahoo Finance
Schroder Investment Management Group Grows Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
What downside risks could hit Apellis Pharmaceuticals Inc. (1JK) stockRecession Risk & AI Optimized Trade Strategies - Newser
Why millennials buy Apellis Pharmaceuticals Inc. (1JK) stockPrice Action & High Accuracy Trade Alerts - Newser
Prudential Financial Inc. Decreases Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Will Apellis Pharmaceuticals Inc. (1JK) stock issue positive guidanceJobs Report & Fast Entry Momentum Trade Alerts - Newser
Why Apellis Pharmaceuticals Inc. (1JK) stock gets analyst attentionRate Cut & High Conviction Buy Zone Picks - Newser
Apellis’ EMPAVELI shows 68% reduction in proteinuria for rare kidney diseases - Investing.com Nigeria
Apellis Reports Positive Phase 3 Results for Its Kidney Disease Treatment Empaveli - marketscreener.com
Apellis (APLS) Gains Boost from Positive Phase 3 Study Results - GuruFocus
Apellis Pharmaceuticals Announces Positive Phase 3 VALIANT Study Results for EMPAVELI in Treating C3 Glomerulopathy and Primary IC-MPGN - Quiver Quantitative
Transcript : Apellis Pharmaceuticals, Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 02 - marketscreener.com
Why Apellis Pharmaceuticals Inc. (1JK) stock could rally stronglyMarket Performance Summary & AI Powered Market Entry Ideas - Newser
Why Apellis Pharmaceuticals Inc. (1JK) stock could be top winnerJuly 2025 Summary & High Yield Equity Trading Tips - Newser
38,572 Shares in Apellis Pharmaceuticals, Inc. $APLS Purchased by Wealthedge Investment Advisors LLC - MarketBeat
Will Apellis Pharmaceuticals Inc. stock deliver long term returnsAnalyst Upgrade & Growth Oriented Trading Recommendations - Newser
Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies | DelveInsight - GlobeNewswire Inc.
Virtus Investment Advisers LLC Acquires 12,106 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Steward Partners Investment Advisory LLC Buys 18,800 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Post Hoc Analysis Confirms Long-Term Benefit of SYFOVRE for Geographic Atrophy - MSN
Geode Capital Management LLC Raises Stake in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Breakout Watch: How risky is Apellis Pharmaceuticals Inc. (1JK) stock compared to peers2025 Valuation Update & Weekly Sector Rotation Insights - BỘ NỘI VỤ
Apellis Pharmaceuticals, Inc. $APLS Position Increased by Rhenman & Partners Asset Management AB - MarketBeat
Apellis Pharmaceuticals (APLS) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Trading the Move, Not the Narrative: (APLS) Edition - news.stocktradersdaily.com
Can Sanmitra Commercial Limited Maintain Its Strong Profit MarginsInterest Rate Changes & High Yield Investment Portfolio - earlytimes.in
Apellis Pharmaceuticals, Inc. $APLS Stock Position Decreased by SG Americas Securities LLC - MarketBeat
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Apellis Pharmaceuticals (Nasdaq: APLS) to Webcast Investor Chats at 2025 Conferences - Stock Titan
Apellis targets 225 EMPAVELI start forms by year-end amid steady SYFOVRE growth and expanded rare kidney launch - MSN
9 Oversold Biotech Stocks to Invest In - Insider Monkey
FY2025 Earnings Estimate for APLS Issued By Zacks Research - MarketBeat
Can Apellis Pharmaceuticals Inc. stock beat analyst upgradesShare Buyback & AI Powered Market Entry Ideas - newser.com
Will Apellis Pharmaceuticals Inc. stock deliver better than expected guidanceQuarterly Growth Report & Daily Oversold Stock Bounce Ideas - newser.com
Does Apellis Pharmaceuticals Inc. (1JK) stock trade below intrinsic valueQuarterly Investment Review & Safe Entry Momentum Tips - newser.com
Apellis Pharmaceuticals Faces Weak Start with 17.3% Gap Down Amid Market Concerns - Markets Mojo
Why Apellis Pharmaceuticals Inc. (1JK) stock stays on buy listsShare Buyback & Safe Swing Trade Setups - newser.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough - 富途牛牛
Using AI based signals to follow Apellis Pharmaceuticals Inc.Gold Moves & Free Safe Entry Trade Signal Reports - newser.com
Apellis Pharmaceuticals Inc. stock prediction for this weekPortfolio Value Report & Stepwise Trade Execution Plans - newser.com
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):